(Circulation. 2000;101:2172.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
From Northwestern Memorial Hospital, Chicago, Ill (C.J.D.); University of Maryland Hospital, Baltimore (W.K.L.); The Care Group, Indianapolis, Ind (J.B.H.); Duke University Medical Center, Durham, NC (J.K.H.); Presbyterian Medical Center, Philadelphia, Pa (W.M.); Lakeland Regional Medical Center, Lakeland, Fla (R.E.V.); Johns Hopkins Hospital, Baltimore, Md (J.A.B.); Christ Hospital/Lindner Center, Cincinnati, Ohio (D.J.K.); Latter Day Saints Hospital, Salt Lake City, Utah (J.B.M.); Washington Hospital Center, Washington, DC (A.L., J.J.P.); Scripps Memorial Hospital, La Jolla, Calif (M.B.); and University of Pennsylvania Medical Center, Philadelphia (J.W.H.).
Correspondence to Charles J. Davidson, MD, Northwestern University Medical School, Feinberg Pavilion, Suite 8-526, 251 E Huron St, Chicago, IL 60611. E-mail cdavidso{at}nmh.org
BackgroundPrevious in vitro and in vivo studies have suggested an association between thrombus-related events and type of contrast media. Low osmolar contrast agents appear to improve the safety of diagnostic and coronary artery interventional procedures. However, no data are available on PTCA outcomes with an isosmolar contrast agent.
Methods and ResultsA multicenter prospective randomized double-blind trial was performed in 856 high-risk patients undergoing coronary artery intervention. The objective was to compare the isosmolar nonionic dimer iodixanol (n=405) with the low osmolar ionic agent ioxaglate (n=410). A composite variable of in-hospital major adverse clinical events (MACE) was the primary end point. A secondary objective was to evaluate major angiographic and procedural events during and after PTCA. The composite in-hospital primary end point was less frequent in those receiving iodixanol compared with those receiving ioxaglate (5.4% versus 9.5%, respectively; P=0.027). Core laboratory defined angiographic success was more frequent in patients receiving iodixanol (92.2% versus 85.9% for ioxaglate, P=0.004). There was a trend toward lower total clinical events at 30 days in patients randomized to iodixanol (9.1% versus 13.2% for ioxaglate, P=0.07). Multivariate predictors of in-hospital MACE were use of ioxaglate (P=0.01) and treatment of a de novo lesion (P=0.03).
ConclusionsIn this contemporary prospective multicenter trial of PTCA in the setting of acute coronary syndromes, there was a low incidence of in-hospital clinical events for both treatment groups. The cohort receiving the nonionic dimer iodixanol experienced a 45% reduction in in-hospital MACE when compared with the cohort receiving ioxaglate.
Key Words: contrast media angioplasty myocardial infarction
This article has been cited by other articles:
![]() |
R. Mehran, E. Nikolsky, A. J. Kirtane, A. Caixeta, S. C. Wong, P. S. Teirstein, W. E. Downey, W. B. Batchelor, P. J. Casterella, Y.-H. Kim, et al. Ionic Low-Osmolar Versus Nonionic Iso-Osmolar Contrast Media to Obviate Worsening Nephropathy After Angioplasty in Chronic Renal Failure Patients: The ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study J. Am. Coll. Cardiol. Intv., May 1, 2009; 2(5): 415 - 421. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Heinrich, L. Haberle, V. Muller, W. Bautz, and M. Uder Nephrotoxicity of Iso-osmolar Iodixanol Compared with Nonionic Low-osmolar Contrast Media: Meta-analysis of Randomized Controlled Trials Radiology, January 1, 2009; 250(1): 68 - 86. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Nguyen, P. Suranyi, J. G. Ravenel, P. K. Randall, P. B. Romano, K. A. Strom, P. Costello, and U. J. Schoepf Iso-Osmolality versus Low-Osmolality Iodinated Contrast Medium at Intravenous Contrast-enhanced CT: Effect on Kidney Function Radiology, July 1, 2008; 248(1): 97 - 105. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-H. Jo, T.-J. Youn, B.-K. Koo, J.-S. Park, H.-J. Kang, Y.-S. Cho, W.-Y. Chung, G.-W. Joo, I.-H. Chae, D.-J. Choi, et al. Renal Toxicity Evaluation and Comparison Between Visipaque (Iodixanol) and Hexabrix (Ioxaglate) in Patients With Renal Insufficiency Undergoing Coronary Angiography: The RECOVER Study: A Randomized Controlled Trial J. Am. Coll. Cardiol., September 5, 2006; 48(5): 924 - 930. [Abstract] [Full Text] [PDF] |
||||
![]() |
Additional Information JAMA, March 15, 2006; 295(11): E7 - E14. [Full Text] [PDF] |
||||
![]() |
B. J. Barrett and P. S. Parfrey Preventing Nephropathy Induced by Contrast Medium N. Engl. J. Med., January 26, 2006; 354(4): 379 - 386. [Full Text] [PDF] |
||||
![]() |
E. K. Fishman Multidetector-row computed tomography to detect coronary artery disease: the importance of heart rate Eur. Heart J. Suppl., August 1, 2005; 7(suppl_G): G4 - G12. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Brinker, C. J. Davidson, and W. Laskey Preventing in-hospital cardiac and renal complications in high-risk PCI patients Eur. Heart J. Suppl., August 1, 2005; 7(suppl_G): G13 - G24. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Bettmann Frequently Asked Questions: Iodinated Contrast Agents RadioGraphics, October 1, 2004; 24(suppl_1): S3 - S10. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Aspelin, P. Aubry, S.-G. Fransson, R. Strasser, R. Willenbrock, K. J. Berg, and the NEPHRIC Study Investigators Nephrotoxic Effects in High-Risk Patients Undergoing Angiography N. Engl. J. Med., February 6, 2003; 348(6): 491 - 499. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bertrand Contrast media--a contradiction? Eur. Heart J., January 2, 2002; 23(2): 172 - 173. [Full Text] [PDF] |
||||
![]() |
C. J. Davidson and W. K. Laskey Contrast media--why the confusion? Eur. Heart J., January 2, 2002; 23(2): 175 - 176. [Full Text] [PDF] |
||||
![]() |
W.B. Batchelor From COURT to HOMBURG: in search of the optimal contrast agent Eur. Heart J., November 1, 2001; 22(21): 2026 - 2028. [PDF] |
||||
![]() |
B. Scheller A reply Eur. Heart J., November 1, 2001; 22(21): 2028 - 2029. [PDF] |
||||
![]() |
R. Schrader Ionic or non-ionic contrast media in stent placement Eur. Heart J., November 1, 2001; 22(21): 2029 - 2029. [PDF] |
||||
![]() |
B. Scheller A reply Eur. Heart J., November 1, 2001; 22(21): 2029 - 2031. [PDF] |
||||
![]() |
V. Legrand Ionic or non-ionic contrast during coronary intervention: does it make a difference? Eur. Heart J., March 1, 2001; 22(5): 353 - 354. [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |